Vaccination of melanoma patients using dendritic cells loaded with an allogeneic tumor cell lysate
/in Dendritic Cells, International Publications, Malignant Melanoma /von 2005-09-27 / Cancer Immunol Immunother 2006 Jul;55(7):819-29B cell tumor vaccine enhanced by covalent attachment of immunoglobulin to surface proteins on dendritic cells
/in International Publications, Malignant Lymphoma /von 2005-09-26 / Clin. Immunol. 2006 Jan;118(1):66-76Vaccination of advanced hepatocellular carcinoma patients with tumor lysate-pulsed dendritic cells: a clinical trial
/in Dendritic Cells, Hepatocellular Carcinoma, International Publications /von 2005-09-01 / J. Immunother. 2005 Sep-Oct;28(5):496-504B-cell lymphoma and myeloma protection induced by idiotype vaccination with dendritic cells is mediated entirely by T cells in mice
/in International Publications, Malignant Lymphoma /von 2005-09-01 / J. Immunother. 2005 Sep-Oct;28(5):461-6[Vaccine therapy of prostate cancer]
/in International Publications, Prostate Cancer /von 2005-09-01 / Aktuelle Urol 2005 Sep;36(5):407-16Immune and clinical outcomes in patients with stage IV melanoma vaccinated with peptide-pulsed dendritic cells derived from CD34+ progenitors and activated with type I interferon
/in International Publications, Malignant Melanoma /von 2005-09-01 / J. Immunother. 2005 Sep-Oct;28(5):505-16Immune-related effects of local hyperthermia in patients with primary liver cancer
/in Hepatocellular Carcinoma, International Publications /von 2005-09-01 / Hepatogastroenterology 2005 Sep-Oct;52(65):1502-6[Current status of hyperthermia for therapy of brain tumor]
/in Glioblastoma, International Publications /von 2005-09-01 / Nippon Rinsho 2005 Sep;63 Suppl 9:483-9Allogeneic dendritic cells pulsed with tumor lysates or apoptotic bodies as immunotherapy for patients with early-stage B-cell chronic lymphocytic leukemia
/in Chronic Leukemia, Dendritic Cells, International Publications /von 2005-09-01 / Leukemia 2005 Sep;19(9):1621-7
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Das IOZK
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- Recent developments in targeting breast cancer stem cells (BCSCs): a descriptive review of therapeutic strategies and emerging therapies
- Neoantigen-targeted dendritic cell vaccination in lung cancer patients induces long-lived T cells exhibiting the full differentiation spectrum
- Individualized Multimodal Immunotherapy (IMI): Scientific Rationale and Clinical Experience from a Single Institution